Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
407.2 USD +8.21% Intraday chart for Medpace Holdings, Inc. +6.46% +32.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Medpace Holdings, Inc., Q1 2024 Earnings Call, Apr 23, 2024
Jefferies Upgrades Medpace Holdings to Buy, Price Target at $450 MT
Medpace Q1 Earnings, Revenue Rise; Updates 2024 Guidance MT
Medpace Guides For FY 2024 GAAP EPS of $10.79-$11.47 on Revenue of $2.15-$2.2 Billion, vs CIQ Analyst Consensus of $10.57/Share on Revenue of $2.18 Billion MT
Earnings Flash (MEDP) MEDPACE HOLDINGS Posts Q1 Revenue $511M, vs. Street Est of $512M MT
Tranche Update on Medpace Holdings, Inc.'s Equity Buyback Plan announced on October 24, 2022. CI
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 CI
North American Morning Briefing : Stock Futures -2- DJ
Deutsche Bank Initiates Coverage on Medpace With Hold Rating, $395 Price Target MT
Medpace Holdings Insider Sold Shares Worth $82,321,250, According to a Recent SEC Filing MT
UBS Adjusts Medpace Price Target to $480 From $452, Maintains Buy Rating MT
Medpace Holdings Insider Sold Shares Worth $8,996,033, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $40,291,000, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $597,923, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $53,406,441, According to a Recent SEC Filing MT
Medpace Holdings Insider Sold Shares Worth $24,992,323, According to a Recent SEC Filing MT
North American Morning Briefing : S&P 500 Seen -2- DJ
The latest transactions by star fund managers Our Logo
UBS Upgrades Medpace to Buy From Neutral, Adjusts Price Target to $452 From $282 MT
Tranche Update on Medpace Holdings, Inc.'s Equity Buyback Plan announced on October 24, 2022. CI
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care Stocks Lower in Afternoon Trading MT
Medpace Shares Rise Following Q4 Earnings Report MT
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 CI
Transcript : Medpace Holdings, Inc., Q4 2023 Earnings Call, Feb 13, 2024
Chart Medpace Holdings, Inc.
More charts
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
376.3 USD
Average target price
417.8 USD
Spread / Average Target
+11.03%
Consensus
  1. Stock Market
  2. Equities
  3. MEDP Stock
  4. News Medpace Holdings, Inc.
  5. Insider Trends: 90-Day Insider Selling Trend Prolonged at Medpace Holdings